Fosfomycin

Chemical formula: C₃H₇O₄P  Molecular mass: 138.059 g/mol  PubChem compound: 446987

Therapeutic indications

Fosfomycin is indicated for:

Osteomyelitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Osteomyelitis and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Osteomyelitis

Population group: only children (1 year - 12 years old)

Osteomyelitis and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Urinary tract infectious disease and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Nosocomial lower respiratory tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Lower respiratory tract infection and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Bacterial meningitis and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacteraemia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Bacteremia and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only children (1 year - 12 years old)

Urinary tract infectious disease and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Nosocomial lower respiratory tract infections

Population group: only children (1 year - 12 years old)

Lower respiratory tract infection and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only children (1 year - 12 years old)

Bacterial meningitis and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacteraemia

Population group: only children (1 year - 12 years old)

Bacteremia and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Osteomyelitis

Population group: only infants (40 days - 1 year old)

Osteomyelitis and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only infants (40 days - 1 year old)

Urinary tract infectious disease and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Nosocomial lower respiratory tract infections

Population group: only infants (40 days - 1 year old)

Lower respiratory tract infection and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only infants (40 days - 1 year old)

Bacterial meningitis and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacteraemia

Population group: only infants (40 days - 1 year old)

Bacteremia and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Osteomyelitis

Population group: only newborns (0 - 40 days old)

Osteomyelitis and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only newborns (0 - 40 days old)

Urinary tract infectious disease and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Nosocomial lower respiratory tract infections

Population group: only newborns (0 - 40 days old)

Lower respiratory tract infection and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only newborns (0 - 40 days old)

Bacterial meningitis and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacteraemia

Population group: only newborns (0 - 40 days old)

Bacteremia and additionally at least one of
Fosfomycin susceptible species
Fosfomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute lower uncomplicated urinary tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Fosfomycin is indicated in the treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis in diagnostic and surgical transurethral procedures

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Fosfomycin is also indicated for prophylaxis in diagnostic and surgical transurethral procedures.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Fosfomycin is contraindicated in the following cases:

Hypersensitivity to fosfomycin

Fosfomycin allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: FOMICYT Powder for solution for infusion
Structured Product Labeling (SPL) 2019: MONUROL Granules for oral solution
Summary of Product Characteristics (SPC) 2016: MONURIL Granules for oral solution
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈